ClinicalTrials.Veeva

Menu

Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor

The Chinese University of Hong Kong logo

The Chinese University of Hong Kong

Status and phase

Unknown
Phase 3

Conditions

Urinary Bladder Tumor

Treatments

Device: Bipolar diathermy
Device: Monopolar diathermy

Study type

Interventional

Funder types

Other

Identifiers

NCT01581723
CUHK_TURB_2012

Details and patient eligibility

About

Bladder cancer is a common urological malignant disease. Patients with bladder cancer will first be managed with transurethral resection (TUR) of bladder tumor. For many years, monopolar transurethral resection of bladder tumor (TURP) has been the gold standard for treatment. However, complications including bleeding, bladder perforation and inadequate sampling of deep tumor biopsy remain the major concerns. Recently published papers suggested that the newer bipolar TUR technology has similar surgical outcomes but less complications comparing with monopolar TUR. In this study, investigators will investigate the benefit of new technology as compared with conventional monopolar resection on tumor clearance, complication and recurrence rates.

Full description

Transurethral resection (TUR) of bladder tumor is one of commonest procedures in urology practice. It is the surgery of choice for staging and treating non-muscle invasive bladder cancer. Short lengths of hospital stay, simple and safe are the main advantages of the surgery. Conventional TUR is performed with monopolar diathermy, which commonly elicits obturator reflexes in lateral-located tumor. However, it is not without complication. Bleeding and bladder perforation with or without obturator reflex are the most significant complications after TUR of bladder tumor. The charring effect of monopolar is also a concern as the diagnosis of muscle invasion by tumor is determined by the integrity of tumor base biopsy. Mariappan et al. reported that as high as 33% of the specimen had no detrusor muscle present for assessment. The absent of muscle not only affect the staging procedure but also associated with higher cancer recurrence rate.

Bipolar resection has been widely used in transurethral resection of prostate (TURP). As compared with the traditional monopolar technology, the electric current passes through the instrument sheath. The advantage of bipolar technology includes less obturator reflex, good hemostasis and early recovery. Study has showed that the cautery artifact is more severe on monopolar resection as compared with bipolar in prostate tissues. Due to the clean and precise cutting, there will be less charring on the specimen and thermal injury to peripheral tissues. Applying to bladder tumor resection, this will improve the staging accuracy with better determination of the depth of invasion. Furthermore, with the use of saline instead of glycine as irrigation fluid, risk of TUR syndrome is minimized. There is no randomized trial on the benefit of using bipolar instrument on TUR bladder cancer. In this study, investigator will investigate the role of bipolar technology in TUR bladder cancer as compared with traditional monopolar resection.

Enrollment

150 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult male or female patients (age ≥ 18)
  • Patients who have diagnosed with bladder cancer (either primary or recurrent) by cystoscopy

Exclusion criteria

  • Patients who are scheduled for second TUR within 6 weeks after the previous TUR

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

150 participants in 2 patient groups

Monopolar TUR
Active Comparator group
Description:
Monopolar diathermy is used to perform tranurethral resection of bladder tumor
Treatment:
Device: Monopolar diathermy
Biploar TUR
Experimental group
Description:
Bipolar diathermy is used to perform transurethral resection of bladder tumor
Treatment:
Device: Bipolar diathermy

Trial contacts and locations

2

Loading...

Central trial contact

Cleo NY Lam, BSc; Eddie SY Chan, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems